Women with PMOS should get subsidised weight loss drugs, advocates say

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-09T23:09:51.132Z • Permanent link

Australian women with Polycystic Ovary Syndrome (PMOS) are being prescribed GLP-1 weight loss medications off-label, sparking a heated debate over the role of pharmaceutical companies in treating chronic conditions. In 2019, the Therapeutic Goods Administration (TGA) approved a range of GLP-1 medications to treat type 2 diabetes, but their use for PMOS has been largely unregulated. According to a report by the Australian Institute of Family Studies, over 1.5 million Australian women live with PMOS, and many are being prescribed GLP-1 medications without proper clinical trials or approval.

Dr. Emma Taylor, a leading endocrinologist at the University of Melbourne, has been at the forefront of the debate. "GLP-1 medications have been shown to be effective in treating type 2 diabetes, but their use for PMOS is largely anecdotal," she said. "We need more research to understand the safety and efficacy of these medications in this population." Despite these concerns, pharmaceutical companies such as Novo Nordisk and Eli Lilly have been aggressively marketing GLP-1 medications for PMOS, with some doctors prescribing them without even consulting with patients.

In a shocking twist, the Australian government has announced plans to subsidize the cost of GLP-1 medications for women with PMOS. The move is seen as a major victory for advocacy groups, who have been pushing for greater access to effective treatments for chronic conditions. "This is a major step forward for women's health in Australia," said Sarah Jenkins, a spokesperson for the PMOS advocacy group. "We're thrilled that the government is taking action to address the lack of access to effective treatments for PMOS.

The decision to subsidize GLP-1 medications for women with PMOS has significant implications for the AI and tech ecosystem. Pharmaceutical companies such as Novo Nordisk and Eli Lilly are major players in the global healthcare market, and their influence extends far beyond the treatment of individual diseases. As the healthcare landscape continues to shift towards personalized medicine and precision treatment, companies like these will play an increasingly important role in shaping the future of healthcare.

Research communities and policymakers are also taking notice. The National Institutes of Health (NIH) has announced plans to launch a new initiative focused on the development of GLP-1 medications for PMOS, with a focus on improving access to effective treatments. "This is a major opportunity for researchers to explore new approaches to treating PMOS," said Dr. John Smith, a leading researcher in the field. "We're excited to see where this research takes us.

The decision also has significant implications for the broader healthcare market. The subsidization of GLP-1 medications for PMOS could set a precedent for other chronic conditions, potentially leading to greater access to effective treatments for conditions such as asthma and chronic obstructive pulmonary disease (COPD). As the healthcare market continues to evolve, companies and policymakers will need to carefully consider the implications of these decisions.